With this novel T2T composite outcome for psoriasis, clinicians and patients can participate in shared decisions on psoriasis treatment goals that can serve as guidance for future treatment steps, -leading to improved management of the disease.
The first age-appropriate and disease-specific instrument to measure health-related quality of life in adolescents with psoriasis has been developed: the APso-QOL.
Zinc was found to have beneficial effects on acne vulgaris, atopic dermatitis, diaper dermatitis, and hidradenitis suppurativa in small studies. Psoriasis and rosacea showed no significant benefit of zinc treatment on disease outcome.
AbbVie announced positive topline data from a phase 3 study evaluating the efficacy and safety of risankizumab (Skyrizi) compared with secukinumab (Cosentyx; Novartis) in adult patients with moderate to severe plaque psoriasis.
Recalcitrant lesions on the anterior lower legs resolved by changing the injection site from the abdomen to the lower legs.
In a novel head-to-head study comparing guselkumab and ustekinumab in both biologic-naive and experienced patients, guselkumab demonstrated a significantly higher probability of achieving and maintaining PASI treatment response through week 40 compared with ustekinumab.
Treatment scenarios with tildrakizumab, such as long-term continuous dosing (up
to 64 weeks), treatment interruption/reinitiation, and switching from another biologic,
can be part of the management of plaque psoriasis with a reasonable expectation
of efficacy and tolerability.
Patients with psoriasis who were prescribed ixekizumab demonstrated longer drug persistence, lower discontinuation rate and lower risk for discontinuation, higher likelihood of adherence, and similar risk for switching compared with patients prescribed secukinumab.
IL-17 and IL-23 inhibitors appear to be well tolerated, with good safety profiles; recent findings outlined here may aid clinical decision making when choosing the most appropriate therapy for patients with moderate to severe psoriasis.
Rates of type 2 diabetes may be higher among patients with psoriasis.
